Niraparib

Zejula

截永樂膠囊

100mg/cap, 30cap/bot

04. ANTINEOPLASTIC AGENTS; ;

04.06. PROTEIN- TYROSINE KINASE INHIBITORS;;

PARP Inhibitor

標靶藥物

X 動物或人體的試驗中或使用經驗發現對胎兒有害，而造成的傷害明顯大於可能的益處。

Unsafe

PO
First-line maintenance treatment of advanced ovarian cancer
Patients <77 kg or with a platelet count <150,000/mm3: 200 mg once daily.
Patients ≥77 kg and with a platelet count ≥150,000/mm3: 300 mg once daily.
Begin treatment within 12 weeks after most recent platinum-containing regimen
Maintenance treatment od recurrent ovarian cancer
300 mg once daily, continue until disease progression or unacceptable toxicity.
Begin treatment within 8 weeks after most recent platinum-containing regimen.
Treatment of advanced ovarian cancer after 3 or more chemotherapies
300mg once daily

Nausea, thrombocytopenia, anemia, fatigue, constipation

1.應整粒吞服，不要咀嚼，壓碎或 撥開
2.可隨餐或空腹服用，睡前服用為可能控制噁心症狀的方法
3.治療期間 及直到最後一 次藥物 服用 後至少 6 個月內，必須使用有效的避孕方法
4.治療期間到最後一劑後 1 個月內，不可哺乳

建立者

103617

建立時間

2023-08-23 09:55:22

維護者

103617

維護時間

2023-08-23 09:59:25